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Peripheral T/NK-cell lymphomas (PTCLs) are rare malignancies characterized by poor prognosis. So far, no standard therapy
has been established, due to the lack of randomised studies. High-dose therapy and autologous stem cell transplantation (HDT-
autoSCT) have shown good feasibility with low toxicity in retrospective studies. In relapsing and refractory PTCL several
comparison analyses suggest similar eﬃcacy for PTCL when compared with aggressive B-cell lymphoma. In the upfront setting,
prospective data show promising results with a long-lasting overall survival in a relevant subset of patients. Achieving a complete
remission at transplantation seems to be the most important prognostic factor. Allogeneic stem cell transplantation (alloSCT)
has been investigated only as salvage treatment. Especially when using reduced intensity conditioning regimen, eligible patients
seem to beneﬁt from this approach. To deﬁne the role for upfront stem cell transplantation a randomised trial by the German
High-Grade Non-Hodgkin Lymphoma Study Group comparing HDT-autoSCT and alloSCT will be initiated this year.
1.Introduction
Peripheral T-cell lymphomas (PTCLs) represent approxi-
mately 10%–15% of all non-Hodgkin’s lymphomas (NHLs)
in Western countries [1–3]. Although the clinical appearance
and the manifestation sites vary widely between the diﬀerent
subgroups, most PTCL share some characteristics. Most
patients are of older age (median age >60 years) and usually
present with advanced stage disease [4, 5]. PTCLs in general
show an aggressive course and most studies detect the T-
cell phenotype as an independent negative prognostic factor
[6–9]. Both, the international prognostic index (IPI) and
the prognostic index for T-cell lymphomas (PITs) that also
include the bone marrow involvement, have shown prognos-
tic value in PTCL and determine the outcome of patients
with nodal PTCL [10–13]. In addition, in retrospective
studies further parameters like the expression of Ki-67, the
level of β2-microglobulin, and the detection of the Epstein-
B a r rv i r u s( E B V )h a v eb e e nf o u n dt oh a v es o m ep r o g n o s t i c
relevance in PTCL [14–16].
The prognosis of PTCL is poor with the exception of
the ALK (anaplastic lymphoma kinase) expressing anaplas-
tic large cell lymphoma (ALCL) with a more favourable
outcome after conventional chemotherapy and the primary
cutaneous T-cell lymphomas (CTCL) that usually show
an indolent clinical course [17, 18]. In contrast, for the
remaining PTCL the outcome following anthracycline-based
chemotherapy is worse compared to aggressive B-cell lym-
phomas even regarding the pre-rituximab era with a median
overall survival (OS) of 9 to 42months [19–21].
So far, no accepted standard treatment could be deﬁned
for PTCL. This mainly results from a lack of PTCL-
restricted randomised trials and the heterogeneity of most
published series. Although the CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone) and CHOP-like
regimen are widely used ﬁrst-line, these protocols have
never been established prospectively in PTCL and are rather
adopted from treatment strategies for aggressive B-cell
lymphomas. Even the role of anthracyclines in the ﬁrst-line
treatment of PTCL is controversial since a large retrospective2 Advances in Hematology
international survey did not reveal a signiﬁcant impact on
OS [5].
To improve the treatment results in PTCL more aggres-
sive strategies such as high-dose therapy with autologous
stem cell transplantation (HDT-autoSCT) and allogeneic
stem cell transplantation (alloSCT) seem attractive strategies
in PTCL. In this paper the data on stem cell transplantation
for PTCL will be discussed.
2. Autologous Stem CellTransplantation
2.1. Second-Line Therapy. HDT-autoSCT has become the
standard of care in relapsing and primary refractory high-
grade B-cell lymphomas. In PTCL, prospective randomized
studies on salvage HDT-autoSCT are lacking. To date, at
least 16 retrospective studies, each including more than 15
patients have addressed this issue and are listed in Table 1
[22–37].
The cited studies were heterogeneous in terms of
histological subgroups, patient characteristics, prognostic
factors, myeloablative regimen, and duration of follow-
up. In addition, some series included patients receiving
upfront autoSCT and did not provide separate analyses
for the patients treated in second line. Taken together,
this strategy is feasible and safe with a low morbidity and
mortality rate. The OS in these series ranged from 35%
at 2years to 70% at 5years, respectively, and the disease-
free survival (DFS) or event-free survival (EFS) from 28%
at 2years to 56% at 5years, respectively. Although the
earlier reports tend to show somewhat better results than
the series published recently, when subgroup or matched
control analyses were performed, the OS results for PTCL
were equivalent to the long-term outcome in patients with
aggressive B-cell lymphomas [22, 26, 32]. So far, it is unclear
whetherhistologyimpactstheoutcomeofPTCLaftersalvage
autoSCT. In some series ALCL showed a favorable outcome
compared to other pathological subtypes [25, 26, 30, 31].
However, the ALK status was not determined in all series
and furthermore, Zamkoﬀ et al. could not demonstrate
a long-term DFS for recurrent (ALK-negative) ALCL fol-
lowing HDT-autoSCT [29]. The encouraging results for
patients with ALCL by Fanin et al., (5-year OS and PFS
of 70% and 56%, resp.) were probably biased by age and
inclusion of patients in ﬁrst complete remission (CR), who
showed a signiﬁcantly better outcome in a subgroup analysis
[23].
The disease status at the time of transplantation often
correlates with the outcome after salvage HDT-autoSCT.
In fact, several authors found a better long-term survival
in patients transplanted in CR than in patients with other
disease status at transplantation [23, 27, 32, 33, 35–37].
Other authors could not conﬁrm this ﬁnding in their survey
[24, 25, 31]. However, since all data in this setting are
generated retrospectively, the value of this observation needs
further observation.
In summary, second-line HDT-autoSCT in PTCL is
feasible and seems an eﬀective approach for a considerable
subgroup of patients.
2.2. First-Line Therapy. S o m er e t r o s p e c t i v es t u d i e so n
upfront HDT-autoSCT have been published and are sum-
marized in Table 2(a) [38–43]. Like in the salvage setting,
a comparison of the cited series is hampered by their
variety. Some series reported mainly on patients with a
low or intermediate low IPI, whereas others predominantly
included patients with an unfavorable prognostic index. In
addition, most studies contained patients receiving HDT-
autoSCT in second line, but not all of them show a subgroup
analysis for the upfront setting. The OS in these retrospective
studies ranged from 53% at 3years to 62–68% at 5 years.
Interestingly, the DFS/EFS did not appear to be much
lower than the OS in most cohorts that might indicate a
substantial curative potential for this approach in previously
untreated PTCL. The EBMT (European Group for Blood
and Marrow Transplantation) published the largest study in
this setting. Kyriakou et al reported data on 146 patients
with angioimmunoblastic T-cell lymphoma (AITL) showing
an actuarial OS of 67% at 2years and 59% at 4years,
respectively, after a median observation of 31months. About
two thirds of the patients were transplanted in ﬁrst CR or
PR. Interestingly, patients who received a TBI- (total body
irradiation-) based conditioning regimen had a signiﬁcantly
lower relapse rate in this study [41].
In these retrospective studies chemotherapy-sensitive
disease was the major factor predicting OS and PFS [39–
41, 43]. Patients transplanted in CR or PR showed a
superior long-term outcome compared to patients with
chemotherapy-refractory disease. Other parameters (e.g.,
age, PIT, IPI) could not consistently be detected as being of
prognostic value.
Although mainly showing promising results, the cited
retrospective studies are limited by focussing on patients,
only, who actually proceed to transplantation leading to
superior results due to patient selection.
Prospective randomized PTCL-restricted studies assess-
ing the value of upfront high-dose therapy in PTCL are
lacking. Two French trials by the GELA (Groupe d’Etude
des Lymphomes de l’Adulte) published data on autoSCT as
frontline strategy in poor-risk, aggressive NHL, including
PTCL [57–59]. In the LNH87-2 study, patients were treated
with either consolidative sequential chemotherapy or HDT-
autoSCT [57, 58]. The LNH93-3 trial compared a high-dose
arm with shortened ﬁrst-line myeloablative chemotherapy
with a sequential consolidation chemotherapy arm. In the
intent-to-treat analysis, none of these studies demonstrated
a signiﬁcant beneﬁt for the high-dose arm [59]. In addition,
a pooled data matched control analysis failed to show a
signiﬁcant advantage for upfront HDT-autoSCT [44, 60].
However, the limited number of patients in the high-
dose group and the restriction to high-risk patients, only,
do not allow to deﬁnitely clarify the impact of ﬁrst-
line HDT-autoSCT in PTCL from these data. In another
subgroup analysis, Nickelsen et al. reported results of 33
patients with PTCL from a single-arm study by the German
High-Grade Non-Hodgkin Lymphoma Study Group [45].
Patients with high-risk aggressive lymphomas were treated
with dose-escalated CHOP plus etoposide necessitating
repeatedautoSCT. Compared to B-cellNHL, PTCL showed aAdvances in Hematology 3
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signiﬁcantlyworseOSandEFSat3yearsinanintent-to-treat
analysis.
So far, ﬁve larger prospective PTCL-restricted trials have
published data on 372 patients with frontline HDT-autoSCT
[46–50]. Compared to the cited retrospective studies, these
prospectiveseriesaremuchmorehomogeneous.Themedian
age ranged between 43 and 57years, PTCL unspeciﬁed; AITL
and ALCL accounted for 77 to 100% of all histological
subtypes; the age-adjusted IPI was high or intermediate
high in 46 to 72%; the most commonly used myeloablative
regimen was the BEAM protocol (n = 228), and the disease
status at transplantation was CR or PR in 59 to 76%.
Only one study included ALK-positive ALCL [46]. In these
trials the OS ranged from 48 to 73% at 3years to 34% at
12years. The DFS/EFS or the progression-free survival (PFS)
was between 36 to 53% at 3years and 30% at 12 years.
One consistently found problem of upfront HDT-autoSCT
is early progressive disease leading to about one third of
patients in intent-to-treat analyses, who ﬁnally fail to achieve
transplantation. Mercadal et al. reported a still signiﬁcant
lower transplantation rate of 41%. Of note, in this trial poor
stem cell mobilization was the second most frequent cause of
failing HDT-autoSCT [48].
With regard to these prospective data, again the remis-
sion status at the time of transplantation was a signiﬁcantly
prognostic factor in most studies that provided this analysis
[46–48]. In addition, the IPI and PIT also show prognostic
v a l u ei ns o m e[ 48, 49] but not in all series [47]. Other
parameters, for example, histological subtype, age, sex, stage
have not been concordantly been found to impact the
outcome. The prospective series on upfront autoSCT are
listed in Table 2(b).
3. Allogeneic Stem CellTransplantation
In contrast to the cytotoxic eﬀect of HDT-autoSCT, allo-
geneic SCT (alloSCT) could add a graft-versus-lymphoma
(GVL) eﬀect to the myeloablative or reduced intensity
conditioning (RIC) regimen, potentially improving the
therapeutic outcome. However, the experience with alloSCT
for PTCL is limited. To date, no relevant data for the
upfront setting are available. Besides some case reports,
ﬁve retrospective series with at least 10 patients have been
reported in patients with relapsing and refractory PTCL
(Table 3(a)) [40, 51–54].
The largest series was published by the Soci´ et´ eF r a n c ¸aise
deGreﬀedeM o¨ elleetdeTh´ erapieCellulaire.In77pretreated
patients who mainly had a myeloablative conditioning regi-
men the 5-year OS and PFS were 57% and 53%, respectively,
after a median followup of 43months. The treatment-related
mortality (TRM) was 33% at 5years. In a multivariate
analysis, chemotherapy-resistant disease at transplantation
and grade 3/4 acute graft-versus-host disease (GVHD) were
the strongest adverse prognostic factors for OS. The TRM
was similar in both conditioning groups [53]. Most studies
could reveal a GVL eﬀect [52–54]. However, the TRM/NRM
(nonrelapse mortality) had a relevant impact on outcome
andwasincreasingovertimeupto69%at3yearsintheseries
by Hamadani et al [52]. The OS ranged from 40% at 2years
to 57% at 5years.
Two prospective studies have been published so far
(Table 3(b))[55,56].IntheItalianphaseIItrialbyCorradini
et al. 17 patients underwent RIC and alloSCT as salvage
therapy [55]. Eight out of 17 patients had failed front-line
HDT-autoSCT. After a median followup of 28 months, 14 of
17patientswerealive.Theestimated3-yearOSandPFSrates
were 81% and 64%, respectively. The TRM was impressively
low with only 6%. Notably, donor lymphocyte infusions
givenatthetimeofprogressionresultedinadiseaseresponse
in two out of four patients, indicating evidence of a GVL
eﬀect. In the German study by Wulf et al. 10 patients were
treated with chemotherapy combined with the humanized
antiCD52 monoclonal antibody, alemtuzumab, followed by
RICandalloSCT.TwopatientshadpriorHDT-autoSCT.The
OS was 70% with six patients in CR after a median followup
of 7months [56].
4. Summary
Due to their generally poor prognosis after conventional
chemotherapy more eﬀective treatment strategies in PTCL
are urgently needed. Although randomised trials are lacking,
HDT-autoSCT can be regarded as feasible and safe in
PTCL. In the salvage setting, several subgroup analysis
and comparisons show similar results compared to diﬀuse
large-cell B-cell lymphoma. This ﬁnding could recently be
conﬁrmed by Sohn et al. [61]. Therefore, taken together the
existing data, HDT-autoSCT seems a reasonable approach
in relapsing and refractory PTCL particularly in those with
chemotherapy-sensitive disease.
The value of upfront HDT-autoSCT remains to be
deﬁnitely established. A recently published retrospective
comparison did not ﬁnd a signiﬁcant beneﬁt of this strategy
compared to conventional treatment [62]. However, in this
study the high-dose group was heterogeneous ranging from
high-dose CHOP to alloSCT. In contrast, other retrospective
studies revealed a signiﬁcant better outcome when HDT-
autoSCT was compared to chemotherapy, alone [5, 36].
Taken together, the prospective data mainly show promising
results, especially for patients achieving a good remission
status prior to transplantation, that has been reported as
independent prognostic factor in most series. Therefore,
these patients should mainly be regarded as candidates for
upfront autoSCT. Since one major obstacle of this approach
is early progressive disease, novel treatment concepts incor-
porating new agents and/or dose-dense regimen should be
further investigated to improve remission status prior to
transplantation. In a subanalysis of several trials by the
DSHNHL (German High-Grade Non-Hodgkin Lymphoma
Study Group), the addition of etoposide to the CHOP-
protocol improved the outcome in younger patients with
PTCL [63]. Furthermore, alemtuzumab has shown eﬃcacy
especially in untreated PTCL [64–67]. However, this agent
can cause signiﬁcant infectious and hematologic toxici-
ties that have led to early closure of some trials [65–
67]. Recently, EBV-associated B-cell lymphomas have been
reportedcomplicatingalemtuzumabtherapyespeciallywhen8 Advances in Hematology
T
a
b
l
e
3
:
S
t
u
d
i
e
s
o
n
H
i
g
h
-
D
o
s
e
T
h
e
r
a
p
y
a
n
d
A
l
l
o
g
e
n
e
i
c
S
t
e
m
C
e
l
l
T
r
a
n
s
p
l
a
n
t
a
t
i
o
n
i
n
P
T
C
L
.
(
a
)
R
e
t
r
o
s
p
e
c
t
i
v
e
d
a
t
a
A
u
t
h
o
r
Y
e
a
r
n
A
g
e
H
i
s
t
o
l
o
g
i
e
s
I
P
I
P
r
e
v
i
o
u
s
a
u
t
o
S
C
T
R
e
g
i
m
e
n
(
M
A
v
e
r
s
u
s
R
I
C
)
S
t
a
t
u
s
a
t
T
x
D
F
S
/
E
F
S
/
P
F
S
O
S
T
R
M
/
N
R
M
F
o
l
l
o
w
u
p
(
m
o
n
t
h
s
)
G
V
H
D
F
e
y
l
e
r
e
t
a
l
.
[
4
0
]
2
0
0
7
1
8
2
8
P
T
C
L
u
5
0
%
T
-
c
e
l
l
l
e
u
k
.
2
8
%
A
L
C
L
1
7
%
C
T
C
L
6
%
0
/
1
3
3
%
≥
2
6
6
%
1
1
%
1
0
0
%
M
A
N
o
d
a
t
a
3
3
%
(
3
y
)
3
9
%
(
3
y
)
3
8
%
∗
5
7
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
2
8
%
E
x
t
.
c
h
r
o
n
i
c
G
V
H
D
:
6
%
M
u
r
a
s
h
i
g
e
e
t
a
l
.
[
5
1
]
2
0
0
5
2
8
3
8
N
K
/
T
7
9
%
B
l
a
s
t
i
c
N
K
1
1
%
N
K
-
l
e
u
k
e
m
i
a
1
1
%
N
o
d
a
t
a
3
2
%
8
2
%
v
e
r
s
u
s
1
8
%
C
R
5
7
%
3
4
%
(
2
y
)
4
0
%
(
2
y
)
2
9
%
3
4
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
2
9
%
E
x
t
.
c
h
r
o
n
i
c
G
V
H
D
:
1
1
%
H
a
m
a
d
a
n
i
e
t
a
l
.
[
5
2
]
2
0
0
8
1
4
4
3
P
T
C
L
u
3
6
%
A
I
T
L
2
8
%
A
L
C
L
1
4
%
N
K
/
T
1
4
%
O
t
h
e
r
7
%
a
a
I
P
I
0
/
1
5
7
%
2
/
3
4
2
%
1
4
%
5
7
%
v
e
r
s
u
s
4
3
%
C
R
2
1
%
P
R
3
5
%
3
1
%
(
3
y
)
3
5
%
(
3
y
)
2
8
%
∗
3
4
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
2
1
%
C
h
r
o
n
i
c
G
V
H
D
:
5
0
%
L
e
G
o
u
i
l
l
e
t
a
l
.
[
5
3
]
2
0
0
8
7
7
3
6
P
T
C
L
u
3
5
%
A
L
C
L
3
5
%
A
I
T
L
1
4
%
O
t
h
e
r
1
6
%
0
/
1
6
1
%
≥
2
3
2
%
U
n
k
n
o
w
n
6
%
2
5
%
7
4
%
v
e
r
s
u
s
2
6
%
C
R
4
0
%
P
R
3
0
%
5
3
%
(
5
y
)
5
7
%
(
5
y
)
2
1
%
∗
4
3
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
2
1
%
K
y
r
i
a
k
o
u
e
t
a
l
.
[
5
4
]
2
0
0
9
4
5
4
8
A
I
T
L
1
0
0
%
N
o
d
a
t
a
3
3
%
5
6
%
v
e
r
s
u
s
4
5
%
C
R
2
7
%
P
R
2
2
%
5
3
%
(
3
y
)
6
4
%
(
3
y
)
1
8
%
∗
2
9
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
1
1
%
E
x
t
.
c
h
r
o
n
i
c
G
V
H
D
:
2
4
%
(
b
)
P
r
o
s
p
e
c
t
i
v
e
d
a
t
a
A
u
t
h
o
r
Y
e
a
r
n
A
g
e
H
i
s
t
o
l
o
g
i
e
s
I
P
I
P
r
e
v
i
o
u
s
a
u
t
o
S
C
T
R
e
g
i
m
e
n
(
M
A
v
e
r
s
u
s
R
I
C
)
S
t
a
t
u
s
a
t
T
x
D
F
S
/
E
F
S
/
P
F
S
O
S
T
R
M
/
N
R
M
F
o
l
l
o
w
u
p
(
m
o
n
t
h
s
)
G
V
H
D
C
o
r
r
a
d
i
n
i
e
t
a
l
.
[
5
5
]
2
0
0
4
1
7
4
1
P
T
C
L
u
5
3
%
A
L
C
L
2
4
%
A
I
T
L
2
4
%
a
a
I
P
I
0
/
1
2
4
%
2
/
3
7
6
%
4
7
%
1
0
0
%
R
I
C
C
R
1
2
%
P
R
7
1
%
6
4
%
(
3
y
)
8
1
%
(
3
y
)
6
%
2
8
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
1
2
%
E
x
t
.
c
h
r
o
n
i
c
G
V
H
D
:
6
%
W
u
l
f
e
t
a
l
.
[
5
6
]
2
0
0
5
1
0
4
5
P
T
C
L
u
4
0
%
A
L
C
L
3
0
%
A
I
T
L
2
0
%
T
-
P
L
L
1
0
%
N
o
d
a
t
a
2
0
%
1
0
0
%
R
I
C
C
R
1
0
%
P
R
5
0
%
6
0
%
(
7
m
)
7
0
%
(
7
m
)
3
0
%
7
A
c
u
t
e
G
V
H
D
◦
3
/
4
:
1
0
%
E
x
t
.
c
h
r
o
n
i
c
G
V
H
D
:
5
0
%
∗
a
t
d
a
y
1
0
0
.Advances in Hematology 9
given in higher dosages [68, 69]. To better deﬁne the role
of chemoimmunotherapy in the concept of HDT-autoSCT,
the Nordic Lymphoma Group is conducting a multicenter
randomized trial using dose-dense chemotherapy induction
with or without alemtuzumab.
Allogeneic stem cell transplantation could oﬀer a cura-
tive option in younger patients. However, the experience
with this approach is sparse and limited to relapsed and
refractory PTCL. In the prospective series nonmyeloablative
conditioning protocols were used with very encouraging
results especially in the Italian study. Furthermore, a GVL
eﬀect could be demonstrated. Taken together, the current
data support the concept of alloSCT in eligible patients with
relapsing chemosensitive PTCL, especially after failing prior
HDT-autoSCT.
Tofurtherinvestigatetheroleofstemcelltransplantation
in previously untreated PTCL, this year the DSHNHL in
cooperationwithothergroupswillinitiateaprospectiveran-
domised multicenter trial comparing upfront autoSCT ver-
sus alloSCT following dose-dense induction chemotherapy.
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